Zimmer Biomet reported Q4 2025 organic constant currency revenue growth of 5.4%, bringing full-year organic growth to 3.9%. Adjusted EPS for the quarter was $2.42 (+4.8% YoY), with full-year EPS at $8.20. Free cash flow remained a strong point, growing over 11% year-over-year to $1.172 billion. Despite solid momentum in new products like the Persona knee and Z1 hip, management issued cautious 2026 guidance for organic revenue growth of just 1-3% and EPS of $8.30-$8.45, citing significant disruption from a strategic overhaul of the U.S. sales force. The company is shifting from a non-dedicated distributor model to a fully dedicated and specialized employee base to close a productivity gap with competitors, a transition expected to be completed by 2027.
| Metric | Value | Change |
|---|---|---|
| Q4 Organic CC Revenue Growth | 5.4% | +5.4% |
| FY 2025 Organic CC Revenue Growth | 3.9% | +3.9% |
| Q4 Adjusted EPS | $2.42 | +4.8% |
| FY 2025 Adjusted EPS | $8.20 | N/A |
| FY 2025 Free Cash Flow | $1.172 billion | +11% |
| 2026 Guidance Organic Revenue Growth | 1% - 3% | N/A |
| 2026 Guidance EPS | $8.30 - $8.45 | N/A |
| Q4 Adjusted Gross Margin | 72.4% | Higher than 2024 |
| 2026 Guidance FCF Growth | 8% - 10% | N/A |
Zimmer Biomet is executing a massive overhaul of its U.S. go-to-market strategy, transitioning from a predominantly independent distributor model (1099) to a dedicated, specialized employee base (W2). Management identified that U.S. productivity is roughly half that of direct competitors, driven by a lack of specialization. By 2027, the company expects to complete this conversion, adding specialized reps in high-growth areas like robotics, S.C.T., and Ambulatory Surgical Centers (ASCs). This is the 'final core initiative' in their turnaround, designed to unlock durable mid-single-digit growth.
The company is leveraging a robust innovation cycle, termed the 'Magnificent Seven,' to drive market share gains. Key drivers include the Persona OsteoTide knee (35% penetration), the Oxford Partial Cementless Knee, and the Z1 hip stem. Robotics and navigation sales surged over 10% in Q4, driven by the strongest capital sales quarter in two years. Management is preparing for the 2027 launch of mBOS, a semi-autonomous robotic system acquired via Monogram, which they believe will be a disruptive technology platform.
Capital allocation priorities have shifted significantly towards shareholder returns. With three recent acquisitions (OrthoGrid, Paragon 28, Monogram) requiring integration and the sales force transition demanding focus, management is pausing M&A to prioritize buybacks. The board authorized up to $1.5 billion in repurchases, with plans for $750 million in 2026. This pivot is supported by strong free cash flow generation, expected to grow 8-10% in 2026, approaching 80% conversion.
Zimmer Biomet is aggressively targeting the Ambulatory Surgical Center (ASC) channel, where penetration for hips and knees reached 20-22% in 2025. The company is hiring specialized ASC reps and optimizing its portfolio for this setting. The Monogram acquisition is particularly strategic here, as its speed and efficiency are tailored to the ASC environment. Partnerships with Geringa and new contract negotiations are expected to further drive momentum in this high-growth segment.
The 2026 guidance implies a significant deceleration in growth, dropping from a Q4 exit rate of 5.4% organic growth to a range of 1-3%. Management explicitly attributed this to 'disruption' from the U.S. sales force transition. While the long-term logic is sound, the immediate financial impact includes a 50-basis-point contraction in operating margins and a 100-basis-point sequential drop in Q1 operating margins, raising concerns about earnings stability during the transition.
Pricing dynamics are deteriorating, with guidance including up to 100 basis points of pricing erosion in 2026 compared to flat pricing in 2025. This pressure stems from biannual price decreases in Japan, reconfiguration in China, and moderation in price increases across EMEA. This deflationary headwind, combined with lower gross margins (guided to 70-71%), suggests a more challenging margin profile even before accounting for transition costs.
Specific segments within the Surgical, Sports, Orthopedics, and Trauma (S.C.T.) division are underperforming. Management admitted that the Trauma business and Restorative Therapies (specifically injections in the U.S.) are 'problem children' that struggled in 2025. While other areas like C.M.F.T. and shoulders are growing mid-teens to high single-digits, the weakness in these specific verticals offsets broader strength and indicates portfolio unevenness.
Integration risks remain elevated as the company manages the assimilation of Paragon 28 and Monogram while simultaneously overhauling the sales force. Paragon 28's contribution in 2025 was slightly below expectations (roughly 20 basis points less than the 270 bps target), and while management committed to double-digit growth for the unit in 2026, the complexity of executing multiple large-scale changes simultaneously increases the risk of operational slip-ups.
Overall: Management displayed a tone of confident pragmatism. CEO Ivan Tornos was emphatic and resolute regarding the necessity of the U.S. sales force transformation, framing it as the 'final core initiative' to unlock durable growth. While acknowledging the short-term pain and disruption reflected in the conservative 2026 guidance, Tornos expressed high excitement about the innovation pipeline and the long-term positioning of the company. CFO Suketu Upadhyay provided detailed, grounded financial context, reinforcing the caution regarding margins while highlighting the strength of free cash flow generation.
Confidence: HIGH - Management is highly confident in the strategic necessity and long-term benefits of the sales force transition, despite the near-term risks. Tornos explicitly stated, 'We feel it is the opportune time to move faster and we will,' and cited data showing productivity gaps that need closing. The confidence is rooted in the successful completion of one-third of the transition and strong product performance.
1% to 3%
$8.30 to $8.45
8% to 10%
Up to 100 basis points of erosion
Up to $750 million
Down approximately 50 basis points from 2025
Hedging & Uncertainty: Management employed frequent hedging language regarding the 2026 outlook, emphasizing the uncertainty of the sales force transition. Phrases like 'risk of disruption,' 'if it goes better than expected,' and 'may move towards the lower range' were used to set expectations. They also used temporal hedges such as 'roughly consistent' growth and 'up to' 100 basis points of pricing erosion. However, hedging was minimal regarding the long-term strategy, where language was assertive ('we will,' 'final step'). This contrast suggests high confidence in the ultimate outcome but low visibility into the short-term execution path.
We're moving from being a company... that has a lot of nondedicated employees... We wanna have 100% of our US Salesforce being dedicated. - Ivan Tornos, CEO
Productivity rates in The US... Are, you know, roughly half. Of what some of our direct competitors have. - Ivan Tornos, CEO
We expect organic constant currency revenue growth of 1% to 3%... This guidance contemplates... the risk of disruption from the U.S. Sales force transition. - Suketu Upadhyay, CFO
We plan to prioritize meaningful return of capital to shareholders over M&A. - Suketu Upadhyay, CFO
The evolution of the US Salesforce represents the final core initiative in a transformation of our organization... it is by far the most crucial step in order to convert Zimmer Biomet into a durable mid-single-digit plus growth company. - Ivan Tornos, CEO
Analyst Sentiment: Analysts were highly focused on the mechanics and risks of the U.S. sales force transition, pressing management on why the disruption was necessary now and why the guidance step-down was so severe. There was skepticism about the timing given the strong Q4 performance, with questions seeking clarity on the 'pacing' of the disruption and the specific 'problem children' in the portfolio.
Management Responses: Management remained consistent and patient, reiterating that the transition is data-driven based on productivity gaps (50% of peers). They deflected concerns about the magnitude of the guide by emphasizing the long-term 'durability' of growth and the 'night and day' difference in specialized territories. They provided granular details on the phasing of margins to reassure investors that the back half of the year would improve.
US Salesforce Transition: Detailed discussion on moving from non-dedicated to dedicated reps, the timeline (completion by 2027), and the productivity gap justification.
Guidance Bridge: Analysts sought to bridge the gap between Q4 mid-single digit growth and 2026 low single digit guidance, with management attributing the difference entirely to transition disruption.
Pricing and Margins: Discussion on the step down in gross margins (70-71% range) and the headwind of 100 bps pricing erosion in 2026.
Paragon 28 Performance: Updates on the integration, noting revenue slightly below expectations but EPS dilution better than expected.
ASC Strategy: Clarification on penetration rates (20-22%) and the strategic fit of the Monogram acquisition.
Zimmer Biomet is undertaking a necessary but painful restructuring of its U.S. sales force to fix a fundamental productivity gap relative to peers. While the long-term thesis of leveraging a 'Magnificent Seven' product cycle with a specialized, dedicated sales team is compelling, the near-term outlook is clouded by significant execution risk. The 2026 guidance for 1-3% growth represents a sharp deceleration from current trends, and margin pressure from pricing and transition costs will weigh on earnings. The shift to prioritize buybacks over M&A is a positive catalyst for valuation support, and FCF remains robust. However, until the sales force transition stabilizes in 2027, the stock is likely to range-bound, warranting a HOLD rating until visibility improves.
Management expects up to 100 basis points of pricing erosion in 2026, driven by biannual price cuts in Japan and market reconfiguration in China, indicating a deflationary pricing environment in key international markets.
FX is expected to be a 50 basis point tailwind to revenue growth in 2026, providing a modest boost despite a weakening dollar throughout 2025.
Guidance assumes a 'stable tariff and policy environment,' suggesting no immediate escalation in trade headwinds compared to the prior year.